Collegium Pharmaceutical, Inc. (NASDAQ:COLL) – Equities research analysts at Jefferies Group cut their FY2021 earnings estimates for Collegium Pharmaceutical in a report released on Tuesday. Jefferies Group analyst D. Steinberg now expects that the specialty pharmaceutical company will post earnings per share of $1.36 for the year, down from their previous forecast of $1.50. Jefferies Group has a “Buy” rating and a $27.00 price target on the stock.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.28. Collegium Pharmaceutical had a negative return on equity of 77.11% and a negative net margin of 447.83%. The company had revenue of $11.95 million for the quarter, compared to the consensus estimate of $5.31 million. During the same quarter last year, the company posted ($1.13) earnings per share. The company’s revenue for the quarter was up 2814.6% compared to the same quarter last year.

Several other equities analysts also recently commented on the company. HC Wainwright initiated coverage on Collegium Pharmaceutical in a report on Monday, September 11th. They set a “buy” rating and a $21.00 price target on the stock. Needham & Company LLC reiterated a “buy” rating and set a $25.00 price target on shares of Collegium Pharmaceutical in a report on Friday, October 6th. Zacks Investment Research upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a report on Monday, November 13th. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $14.00 price target on shares of Collegium Pharmaceutical in a report on Friday, September 8th. Two research analysts have rated the stock with a sell rating and six have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $23.50.

Shares of Collegium Pharmaceutical (NASDAQ:COLL) traded down $0.64 during mid-day trading on Wednesday, reaching $17.70. The company’s stock had a trading volume of 1,342,032 shares, compared to its average volume of 515,147. Collegium Pharmaceutical has a one year low of $7.37 and a one year high of $20.92.

In other news, CEO Michael Thomas Heffernan sold 50,000 shares of the stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $15.53, for a total value of $776,500.00. Following the completion of the sale, the chief executive officer now directly owns 558,987 shares of the company’s stock, valued at $8,681,068.11. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CTO Alison B. Fleming sold 4,029 shares of the stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $17.00, for a total value of $68,493.00. Following the completion of the sale, the chief technology officer now directly owns 28,513 shares of the company’s stock, valued at $484,721. The disclosure for this sale can be found here. In the last quarter, insiders have sold 58,630 shares of company stock worth $924,360. Corporate insiders own 25.76% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Pura Vida Investments LLC bought a new stake in shares of Collegium Pharmaceutical in the third quarter valued at approximately $1,229,000. Wells Fargo & Company MN boosted its position in shares of Collegium Pharmaceutical by 12.8% in the third quarter. Wells Fargo & Company MN now owns 45,254 shares of the specialty pharmaceutical company’s stock valued at $475,000 after acquiring an additional 5,136 shares during the period. Citadel Advisors LLC boosted its position in shares of Collegium Pharmaceutical by 773.8% in the third quarter. Citadel Advisors LLC now owns 544,033 shares of the specialty pharmaceutical company’s stock valued at $5,707,000 after acquiring an additional 481,771 shares during the period. JPMorgan Chase & Co. bought a new stake in shares of Collegium Pharmaceutical in the third quarter valued at approximately $192,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of Collegium Pharmaceutical in the third quarter valued at approximately $201,000. 79.98% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This article was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/12/08/jefferies-group-weighs-in-on-collegium-pharmaceutical-inc-s-fy2021-earnings-coll.html.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Stock Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.